Biogen Aktie

165,05 EUR -0,10 EUR -0,06 %

18:18:32

STU

195,33 USD -0,08 USD -0,04 %

18:19:21

BTT

Biogen jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.24,37 Mrd. EUR

KGV20,02Div. Rendite0,00%

WKN789617

ISINUS09062X1037

SymbolBIIB

Biogen Aktien News

Sortieren:Datum Meistgelesen

04.09.24GlobeNewswireBiogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

22.08.24PR NewswireLeqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

31.07.24PR NewswireAlcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen

30.07.24GlobeNewswireNew Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alz

30.07.24PR NewswireNew Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The...

30.07.24GlobeNewswireBiogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

26.07.24GlobeNewswireUpdate on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

22.07.24PR NewswireBiogen Inc. Sued for Securities Law Violations - Contact the Schall Law Firm to Discuss Your Legal Rights BIIB

16.07.24PR NewswireBiogen Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BIIB

10.07.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB

10.07.24PR NewswireBiogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB

08.07.24PR NewswireShareholders that lost money on Biogen Inc.(BIIB) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

02.07.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB

02.07.24GlobeNewswireBiogen Completes Acquisition of Human Immunology Biosciences

28.06.24GlobeNewswire“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China

26.06.24PR NewswireBIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit

24.06.24GlobeNewswireTOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union

18.06.24PR NewswireLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2024 in Biogen Lawsuit - BIIB

10.06.24GlobeNewswireFDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

10.06.24PR NewswireFDA Accepts Eisai's Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

05.06.24PR NewswireFINAL DEADLINE RAPIDLY APPROACHING: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm

30.05.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen Inc. of Class Action Lawsuit and Upcoming Deadlines - BIIB

30.05.24GlobeNewswireBiogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

30.05.24PR NewswireBIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

22.05.24GlobeNewswireBiogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

16.05.24GlobeNewswireBiogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

16.05.24PR NewswireIonis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

15.05.24GlobeNewswireEisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track St

15.05.24PR NewswireEisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Trac...

25.04.24GlobeNewswireBiogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®

01.04.24PR NewswireEisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

11.03.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB

06.03.24GlobeNewswireNew Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

04.03.24GlobeNewswireBiogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

03.03.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB

23.02.24GlobeNewswireBiogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

12.02.24GlobeNewswireBiogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

31.01.24GlobeNewswireBiogen to Realign Resources for Alzheimer's Disease Franchise

19.12.23GlobeNewswireCentralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission

15.12.23GlobeNewswireCHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease

Biogen News

Biogen News: auf dieser Seite finden Sie alle Biogen News und Nachrichten zur Biogen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Biogen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Biogen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.